ASX-173
Based on 1 Customer Validation
ASX-173 is an orally active inhibitor of asparagine synthetase (ASNS) (IC50 = 0.113 μM, Ki = 0.4 nM). ASX-173 enhances the anticancer activity of L-asparaginase (ASNase) (HY-P1923). ASX-173 disrupts nucleotide synthesis and induces leukemia cell cycle arrest, apoptosis and autophagy in leukemia cells in combination with ASNase. ASX-173 slows the growth of OCI-AML2 xenografts in combination with ASNase. ASX-173 is indicated for the study of acute lymphoblastic leukemia, acute myeloid leukemia, colorectal cancer, and other cancers.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.47%
- CAS. Nr.: 2748800-08-8
- Formel: C28H30FN3O3
- Molecular Weight:475.55
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle Caspase Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Caspase 3 |
ASX-173 (0.1-1000 nM,24 h) suppresses transcription of several endogenous Wnt target genes, including AXIN1, DKK1, CD133/PROM1, and MYC in HCT-116 cells[1].
ASX-173 exhibits potent cytotoxicity in DMEM medium but minimal to no effect when cells were cultured in RPMI-1640 in MDA-MB-231, SW620, A375 cells[1].
ASX-173 (0-500 nM) restores sensitivity to ASNase (HY-P1923) in ASNS-deficient RS4;11 cells[1].
ASX-173 (0-1250 nM) enhances the ASNS-positive cancer cell lines anticancer activity of ASNase in OPM-2, MOLP-8, AMO-1, Jurkat, H929, MV4;11, HT1080 cells[1].
ASX-173 (0-1500 nM) increases sensitivity combination with ASNaseWT or a glutaminase-deficient ASNase variant (ASNaseQ59L)13 in OVCAR-8, 92.1_D3, 92.1_M3 and OCI-AML2 cells[1].
ASX-173 (0-1500 nM) shows anticancer activity of majority of tested lines (such as: MV4;11, Jurkat, A172) under Asparagine (HY-N0667)-deprived conditions, using either asparagine-free medium or low-dose ASNase (0.025 IU/mL)[1].
ASX-173 (0-500 nM, 48 h) induces cell cycle arrest and activates apoptosis and autophagy under Asparagine-depleted conditions in MV4;11 leukemia and RS4;11_ASNS cells[1].
ASX-173 (80 nM, 24 h) disrupts nucleotide biosynthesis in OCI-AML2 leukemia cells treated with 0.025 IU/mL ASNase (Spectrila)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCT-116 cells
-
Concentration:0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM
-
Incubation Time:24 h
-
Result:Suppressed transcription of several endogenous Wnt target genes, including AXIN1, DKK1, CD133/PROM1, and MYC.
-
Cell Line:MV4;11 leukemia/RS4;11_ASNS cells
-
Concentration:0 nM, 5 nM, 50 nM, 500 nM
-
Incubation Time:48 h
-
Result:Did not significantly alter cell cycle distribution when asparagine-deficient media or ASX-173 treatment alone.
Led to pronounced changes in cell cycle dynamics, increased the sub-G1 population accompanied and decreased G2/M and S phase populations, indicating enhanced cell cycle arrest in G1/G0 and apoptotic cell death under Asparagine-deprived conditions.
Up-regulated p27, down-regulated p21 under Asparagine-deprived conditions.
-
Cell Line:MV4;11 leukemia/RS4;11_ASNS cells
-
Concentration:0 nM, 5 nM, 50 nM, 500 nM
-
Incubation Time:48 h
-
Result:Increase the expression levels of cleaved caspase-3 , cleaved PARP and phosphorylation of AKT, p70S6K, and ERK1/2 under Asparagine-deprived conditions.
Down-regulated the autophagic marker LC3 under Asparagine-deprived conditions.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NSG mice xenografted with luciferase-expressing OCI-AML2 leukemia cells (0.5 × 106)[1]
-
Dosage:50 mg/kg + ASNase (5,000 IU/kg, i.p.)
-
Administration:p.o., once a day, 2 weeks
-
Result:Suppressed leukemia progression, whereas monotherapy with either agent showed no significant effect.
Achieved a 7-day growth delay over the monotherapies, representing approximately 3-4 leukemia doubling times.
Improved overall survival, with all combination-treated mice living 7-10 days longer than those in other treatment groups.
Chemical Information
-
CAS. Nr. 2748800-08-8
-
Appearance Solid
-
Molecular Weight 475.55
-
Formel C28H30FN3O3
-
Color White to off-white
-
SMILES
CC[C@@H](C(N1C[C@@H](C2=CC=C(C=C2)F)[C@H](O)[C@@H]1C(NC(C3=CC=CC=C3)C4=CC=CC=C4)=O)=O)N
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (210.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.26 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.26 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (286 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1028 mL | 10.5141 mL | 21.0283 mL | 52.5707 mL |
| 5 mM | 0.4206 mL | 2.1028 mL | 4.2057 mL | 10.5141 mL | |
| 10 mM | 0.2103 mL | 1.0514 mL | 2.1028 mL | 5.2571 mL | |
| 15 mM | 0.1402 mL | 0.7009 mL | 1.4019 mL | 3.5047 mL | |
| 20 mM | 0.1051 mL | 0.5257 mL | 1.0514 mL | 2.6285 mL | |
| 25 mM | 0.0841 mL | 0.4206 mL | 0.8411 mL | 2.1028 mL | |
| 30 mM | 0.0701 mL | 0.3505 mL | 0.7009 mL | 1.7524 mL | |
| 40 mM | 0.0526 mL | 0.2629 mL | 0.5257 mL | 1.3143 mL | |
| 50 mM | 0.0421 mL | 0.2103 mL | 0.4206 mL | 1.0514 mL | |
| 60 mM | 0.0350 mL | 0.1752 mL | 0.3505 mL | 0.8762 mL | |
| 80 mM | 0.0263 mL | 0.1314 mL | 0.2629 mL | 0.6571 mL | |
| 100 mM | 0.0210 mL | 0.1051 mL | 0.2103 mL | 0.5257 mL |
ASX-173 Related Classifications
HY-175282 Related Classifications
Powered by Bioz